Reportedly, Merck & Co., Inc. (MRK) has entered an agreement with the United States Government development, manufacture, and initial distribution of an investigational biological therapeutic, MK-7110 upon approval or Emergency Use Authorization from the U.S. Food and Drug Administration (FDA).
Merck will get $356 million approximately for manufacturing and supply of 60,000-100,000 doses of MK-7110 to the U.S. Government through June 30, 2021, to cover the government’s Operation Warp Speed goals and speeding delivery of MK-7110 to the American people as quickly as possible.
“Building upon the promising clinical findings to date for MK-7110, Merck is pleased to be collaborating with the U.S. Government to advance the manufacture and distribution of this candidate for patients with serious COVID-19 disease,” stated Dr. Roger M. Perlmutter, president, Merck Research Laboratories.
Merck acquired MK-7110 through its acquisition of OncoImmune, a privately held, clinical-stage biopharmaceutical company.
An interim analysis by OncoImmune reported data from 203 participants showed that hospitalized patients with COVID-19 treated with a single dose of MK-7110 reported a 60% higher probability of improvement in clinical status compared to a placebo, as defined by the protocol. The risk of death or respiratory failure was also reduced by more than 50%. The study reportedly is still ongoing.
Merck & Co., Inc. (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century. They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.